A Placebo- and Positive-Controlled Study of the Electrophysiological Effects on the QT Interval After a Supratherapeutic Dose of LY2140023 in Subjects With Schizophrenia
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2012
At a glance
- Drugs Moxifloxacin; Pomaglumetad methionil
- Indications Schizophrenia
- Focus Pharmacodynamics
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 11 Jun 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 29 May 2012 New trial record